Marktanalyse - Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2017

Global Markets Direct
02.2017
57 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Prader-Willi Syndrome (PWS) - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prader-Willi Syndrome (PWS) — Pipeline Review, H1 2017, provides an overview of the Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline landscape.

Prader-Willi Syndrome (PWS) is a rare genetic disorder present at birth that results in a number of physical, mental and behavioral problems. Symptoms include poor muscle tone, low levels of sex hormones and a constant feeling of hunger.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prader-Willi Syndrome (PWS) — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prader-Willi Syndrome (PWS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Prader-Willi Syndrome (PWS) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Prader-Willi Syndrome (PWS) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Prader-Willi Syndrome (PWS) (Genetic Disorders)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Prader-Willi Syndrome (PWS) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Prader-Willi Syndrome (PWS) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Prader-Willi Syndrome (PWS) - Overview

Prader-Willi Syndrome (PWS) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Prader-Willi Syndrome (PWS) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Prader-Willi Syndrome (PWS) - Companies Involved in Therapeutics Development

Alize Pharma SAS

Essentialis Inc

INSYS Therapeutics Inc

LG Chem, Ltd.

Saniona AB

Prader-Willi Syndrome (PWS) - Drug Profiles

(metoprolol + tesofensine) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZP-531 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BSN-175 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cannabidiol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carbetocin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

diazoxide choline CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Eutropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-04 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KAL-671 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate snRNP-N for Prader-Willi Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Glycogen Synthase for Prader-Willi Syndrome and Glycogen Storage Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Prader-Willi Syndrome (PWS) - Dormant Projects

Prader-Willi Syndrome (PWS) - Discontinued Products

Prader-Willi Syndrome (PWS) - Product Development Milestones

Featured News & Press Releases

Nov 07, 2016: Saniona Plans To Initiate Phase 2A Study In Prader-Willi In 2017

Jul 20, 2016: Kalytera Therapeutics Presents New Data Demonstrating KAL671 Ability to Prevent Bone Loss in a Prader-Willi Syndrome Animal Model

Jul 18, 2016: Alize Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences

Jul 05, 2016: Kalytera Therapeutics to Present New Data That Supports the Continued Investigation of KAL671 for the Treatment of Osteoporosis in Prader-Willi Syndrome at the IPWSO Conference

Apr 26, 2016: Alize Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome

Jan 07, 2016: Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome

Sep 24, 2015: FDA Office of Orphan Products Development Awards Rhythm $1 Million Grant to Support Phase 2 Study of Setmelanotide in Prader-Willi Syndrome

Jun 04, 2015: Rhythm Initiates Two Phase 2 Clinical Trials of Setmelanotide in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies

Mar 02, 2015: Alize Pharma launches Phase II clinical trial of AZP-531 in Prader-Willi syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Prader-Willi Syndrome (PWS) - Pipeline by Alize Pharma SAS, H1 2017

Prader-Willi Syndrome (PWS) - Pipeline by Essentialis Inc, H1 2017

Prader-Willi Syndrome (PWS) - Pipeline by INSYS Therapeutics Inc, H1 2017

Prader-Willi Syndrome (PWS) - Pipeline by LG Chem, Ltd., H1 2017

Prader-Willi Syndrome (PWS) - Pipeline by Saniona AB, H1 2017

Prader-Willi Syndrome (PWS) - Dormant Projects, H1 2017

Prader-Willi Syndrome (PWS) - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Prader-Willi Syndrome (PWS), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus